Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Minimal Residual Disease Testing Companies

Minimal Residual Disease (MRD) testing is a technique used in oncology to detect and monitor small amounts of cancer cells that may remain in a patient's body after treatment. It helps assess the effectiveness of treatment and predict the likelihood of disease recurrence.

Minimal Residual Disease Testing Key Companies

Latest Minimal Residual Disease Testing Companies Update:

Adaptive Biotechnologies Launched clonoSEQ for assessing MRD in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA), expanding their product portfolio and competitive edge.

Guardant Health Received FDA approval for LUNAR-TRIDENT assay for MRD detection in triple-negative breast cancer, increasing their presence in the solid tumor MRD market.

Natera Collaborated with AstraZeneca to develop and commercialize MRD tests for non-small cell lung cancer (NSCLC), leveraging their expertise in liquid biopsy technologies.

Exact Sciences Corporation Announced plans to acquire Astex Pharmaceuticals, gaining access to their MRD technology for colorectal cancer, strengthening their dominant position in this segment.

List of Minimal Residual Disease Testing Key companies in the market

Adaptive Biotechnologies (US)

Sysmex Inostics, Inc. (US)

Arup Laboratories Inc. (US)

ArcherDX, Inc. (US)

Asuragen Inc. (US)

Bio-Rad Laboratories, Inc. (US)

Guardant Health (US)

QIAGEN N.V. (Germany)

FOUNDATION MEDICINE, INC. (US)

GRAIL, Inc. (US)

Minimal Residual Disease Testing Market Highlights:

Minimal Residual Disease Testing Market Size

Minimal Residual Disease Testing Market Trends

Minimal Residual Disease Testing Market Analysis

Minimal Residual Disease Testing Market Share

Minimal Residual Disease Testing Market Highlights:

Minimal Residual Disease Testing Market Trends

Minimal Residual Disease Testing Market Analysis

Minimal Residual Disease Testing Market Share

Minimal Residual Disease Testing Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.